The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 421-427

  McIntyre, Roger S ^a,b   Alsuwaidan, Mohammad ^a,b   Soczynska, Joanna K ^a,b   Szpindel, Isaac ^c   Bilkey, Timothy S ^d   Almagor, Doron ^a,b   Woldeyohannes, Hanna O ^b   Powell, Alissa M ^b   Cha, Danielle S ^a,b   Gallaugher, Laura Ashley ^b   Kennedy, Sidney H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c The START Clinic   (Canada)

^d Ontario Bilkey ADHD Clinics   (Canada)

Author keywords

ADHD; bipolar disorder; BMI; leptin; lisdexamfetamine dimesylate; metabolic

Indexed keywords

ADIPONECTIN; GHRELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LISDEXAMFETAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC PARAMETERS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; PRIORITY JOURNAL; PULSE RATE; SCORING SYSTEM;

ADHD; BIPOLAR DISORDER; BMI; LEPTIN; LISDEXAMFETAMINE DIMESYLATE; METABOLIC;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; BODY WEIGHT; DEXTROAMPHETAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884166590     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2325     Document Type: Article

References (19)

1. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al,. 2008 Sep. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69 (9): 1364-73.
2. Amsterdam JD, Shults J,. 2010. Jul. Efficacy and safety of long-term fluoxetine versus lithium Monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 167 (7): 792-800.
3. Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, et al,. 2012 Feb. The Canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 24 (1): 23-37.
4. Brown TE, Brams M, Gasior M, Adeyi B, Babcock T, Dirks B, et al,. 2011. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin 27 Suppl 2: 23-33.
5. Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK,. 2012 Jan. Placebo-controlled adjunctive trial of Pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 73 (1): 103-12.
6. Charach G, Kaysar N, Grosskopf I, Rabinovich A, Weintraub M,. 2009 Jul. Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data. J Clin Pharmacol 49 (7): 848-51.
7. Gentil V,. 2009 Aug. Bipolar disorder and concurrent psychiatric and medical disorders. J Clin Psychiatry 70 (8): e29.
8. Goodman DW,. 2007 Aug. Lisdexamfetamine dimesylate: the first prodrug stimulant. Psychiatry (Edgmont) 4 (8): 39-45.
9. Krishnan S, Moncrief S,. 2007 Jan. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 35 (1): 180-4.
10. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, et al,. 2007 Mar. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 68 (3): 390-8.
11. McIntyre R., 2009 Jul. Bipolar disorder and ADHD: clinical concerns. CNS Spectr 14 (7 Suppl 6): 8-9.
12. McIntyre RS, Keck PE, Jr., 2006 Dec. Comorbidity in bipolar disorder: clinical and research opportunities. Bipolar Disord 8 (6): 645-7.
13. McIntyre RS, Konarski JZ, Yatham LN,. 2004. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 19 (6): 369-86.
14. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CW, Miranda A, et al,. 2007 Jul. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry 20 (4): 406-16.
15. Najib J., 2009 Jan. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d -amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 31 (1): 142-76.
16. Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, et al,. 2005 Jun 1. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 57 (11): 1467-73.
17. Osby U, Brandt L, Correia N, Ekbom A, Sparen P,. 2001 Sep. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58 (9): 844-50.
18. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L,. 2009 Oct. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 14 (10): 573-85.
19. Yatham LN, Kennedy SH, O'Donovan C, et al,. 2005. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 7 Suppl 3: 5-69.